Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma - Report - MDSpire

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

  • By

  • Mahir Hasan

  • Wolfram Samlowski

  • Samer Nakhle

  • May 8, 2026

  • 0 min

Share

Clinical Report: Elevated Rates of Hypopituitarism After Ipilimumab and Nivolumab

Overview

Routine monitoring of patients undergoing ipilimumab and nivolumab therapy for metastatic melanoma revealed a high incidence of hypopituitarism and hypothyroidism. Endocrinopathy was detected in 44.1% of patients, with hypopituitarism occurring in 18.7% and primary hypothyroidism in 25.4%.

Background

The combination of ipilimumab and nivolumab has significantly improved survival rates in metastatic melanoma patients. However, this treatment is associated with a range of immune-related adverse events, particularly endocrinopathies such as hypopituitarism. Understanding the incidence and management of these side effects is crucial for optimizing patient care and treatment outcomes.

Data Highlights

FindingPercentage
Endocrinopathy44.1%
Hypopituitarism18.7%
Primary Hypothyroidism25.4%
Median Time to Onset of Hypopituitarism72.5 days
Median Time to Onset of Hypothyroidism58 days

Key Findings

  • Endocrinopathy was detected in 44.1% of patients receiving combination therapy.
  • Hypopituitarism occurred in 18.7% of patients.
  • Primary hypothyroidism was observed in 25.4% of patients.
  • The median time to onset for hypopituitarism was 72.5 days.
  • Prompt endocrine replacement therapy was initiated for all affected patients.
  • Only one patient required hospitalization due to symptomatic hypopituitarism.

Clinical Implications

Routine monitoring for hypopituitarism and other endocrinopathies is essential for patients undergoing ipilimumab and nivolumab therapy. Early detection and prompt management of these conditions can help minimize complications and support the continuation of immunotherapy.

Conclusion

The high incidence of hypopituitarism and other endocrinopathies in patients treated with ipilimumab and nivolumab underscores the need for regular endocrine monitoring. This proactive approach can enhance patient safety and treatment efficacy.

Related Resources & Content

  1. The ASCO Post, 2021 -- Adverse Events in Patients With Melanoma Treated With Ipilimumab: Results of a Toxicity Monitoring Program
  2. The ASCO Post, 2021 -- Extended Follow-up of Nivolumab/Ipilimumab for Metastatic Melanoma
  3. The ASCO Post, 2025 -- Immunotherapy for Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy
  4. Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors - PMC
  5. The ASCO Post — Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma
  6. FDA Drug Evaluation
  7. Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors - PMC
  8. National Comprehensive

Original Source(s)

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

  • by Mahir Hasan, Wolfram Samlowski, Samer Nakhle

  • May 8, 2026

Related Content

Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis

Modeling the Genetics of Uveal Melanoma

Researchers have developed a genetically engineered mouse model that mirrors the genetic evolution of uveal melanoma

  • April 21, 2026

  • 3 min
2025 San Antonio Breast Cancer Symposium Recap

Harold Burstein, MD, PhD, summarizes important breakthroughs presented at the 2025 San Antonio Breast Cancer Symposium.

  • March 17, 2026

  • 1 min